Abstracts / Biol Blood Marrow Transplant 23 (2017) S18–S391 172 Anti-CD 19 and Anti- CD 20 Chimeric Antigen ReceptorModified T Cells for B-Cell Malignancies: A Systematic Review and Meta-Analysis Irbaz bin Riaz 1, Muhammad Husnain 1, Muhammad Umar 2, Ali McBride 3, Anh Hua 4, Umar Zahid 1, Auon Abbas Hamadani 5, Laeth George 6, Zeeshan Ali 7, Qurat-ul-Ain Riaz Spira 1, Ammad Raina 8, Bushra Rahman 4, Soham Puvvada 1,9, Faiz Anwer 10. 1 Department of Medicine, University of Arizona, Tucson, AZ; 2 Department of Medicine, Bronx-Lebanon Hospital center, Bronx, NY; 3 Barnes Jewish Medical Center, Saint Louis, MO; 4 University of Arizona, Tucson, AZ; 5 Department of vascular surgery, University of Arizona, Tucson, AZ; 6 University of Arizona College of Medicine, Phoenix, AZ; 7 Department of Medicine, Tucson Medical Center, Tucson, AZ; 8 Southwestern University Phoenix, AZ, Phoenix, AZ; 9 Arizona Cancer Center, Tucson, AZ; 10 Hematology Oncology and Stem cell Transplant., University of Arizona, Tucson, AZ Background: Chimeric antigen receptor (CAR) modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 CAR-T therapy for B-cell hematologic malignancies. Methods: The meta-analysis was designed in accordance with the principles set by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. A comprehensive Literature search was performed using MEDLINE (Ovid SP and PubMed), EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews (CDSR) and Cochrane Central Register of Controlled Trials (CENTRAL), Scopus and Web of Science. We performed a meta–analysis using Comprehensive Meta-analysis 3.0 using random effects model. The heterogeneity was assessed using I2values. Results: A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate (OR) of 61% (118/195) with CR of 42% (81/195) and PR of 19% (37/195). OR was 78% with HR of .75 (95% CI .55-.88, P = .014) for ALL, 51% with HR of .54 (95% CI .35-.72, P = .67) for CLL and 51% with HR of .51 (95% CI of .39-.63, P = .88) for NHL. Major adverse events were cytokine release syndrome (CRS) 33%, HR of .37 (95% CI .26-.44, P = .001), Neurotoxicity 33%, HR of .35 (95% CI .27-.44, P = .001) and B cell aplasia 54% with HR of .43 (95% CI .15-.77, P = .72). Conclusion: Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia especially in ALL patients. 173 Blinatumumab as a Bridge to Transplant in ALL and the First Reported Use in Myeloma: Successes in Reaching Transplant but with Rapid Relapse. the Mount Sinai Hospital’s Institutional Experience Kelsey A. Sokol 1, Bart Barlogie 2, Amir Steinberg 3. 1 Icahn School of Medicine at Mount Sinai, New York, NY; 2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; 3 Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai, New York, NY Background: Allogeneic hematopoietic stem cell transplantation is the only potential curative option for patients with relapsed/refractory acute lymphoblastic leukemia. The following is our experience using blinatumomab in relapsed/ S143 refractory Philadelphia chromosome-negative B cell ALL and Burkitt lymphoma as a bridge to stem cell transplant at Mount Sinai Hospital. Methods: Retrospective analysis of the tolerability and outcomes for patients receiving blinatumomab prior to SCT in 2015 as part of quality assurance review. Results: Blinatumomab was administered to 5 patients (1 female) with a median age of 36 (range 27-64). Four patients had a diagnosis of relapsed/refractory Philadelphia chromosome-negative ALL and 1 patient had a diagnosis of Burkitt lymphoma (BL). The median number of treatment regimens received prior to blinatumomab was 3 (range 2-6) and median number of days from diagnosis to initiation of blinatumomab was 252 (range 170-417). Cycle 1 was incomplete in 1 patient with ALL and the patient with Burkitt lymphoma secondary to sepsis and progression of disease, respectively. Neither of these 2 patients underwent ASCT. Of the remaining 3 patients, one completed 2 cycles of blinatumomab with complete morphologic remission and evidence of minimal residual disease by cytogenetics The second patient also completed 2 cycles with complete morphologic remission and normal cytogenetics before and after treatment. The final patient completed 3 cycles of blinatumomab and achieved complete morphologic and cytogenetic remission. Median time to SCT in these 3 patients was 27 days (range 18-35) and median time to relapse post SCT was 73 days (range 60-106). In all five patients, the median number of doses received inpatient was 25 (range 10-56) with the remaining doses received at home through continuous infusion. Blinatumomab was generally well tolerated with no patient experiencing cytokine release syndrome. As part of our institutional experience, we administered blinatumumab to one patient with IgG kappa myeloma who previously received 14 lines of therapy. Blincyto was given as a last resort as myeloma cells express CD19. He received 20 days total with complications and without significant improvement, and was discharged to hospice care. This patient’s information is not included in the statistical analysis. Conclusions: Of our 5 patients who received blinatumomab for ALL/BL, 3 patients achieved complete remission and underwent allogeneic hematopoietic stem cell transplantation. Unfortunately, all 3 transplant patients relapsed shortly thereafter. In this small sample size, we conclude that blinatumomab as a bridge to transplant did not significantly prolong survival. Infusion-related toxicity or side effects of ALL therapy prevented the ideal transition from inpatient to outpatient infusion. Cost-benefit analysis will need to be considered in the future for this drug. 174 Efficacy, Safety and Outcomes of Various Donor Lymphocyte Infusion Strategies after Allogenic Stem Cell Transplantation: Single-Centre Experience Manoj Toshniwal, Anant Gokarn, Sachin Punatar, Subhadeep Bose, Alok Gupta, Libin Mathew, Sadhana Kannan, Deepa Philip, Navin Khattry. Dept of Medical Oncology, Tata Memorial Centre, Navimumbai, India Relapse is the most frequent cause of failure after allogenic stem cell transplantation (allo-SCT) for hematologic malignancies and it carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients. Donor lymphocyte infusions (DLIs) can induce remission in these patients and help to avoid an expensive and difficult second transplant.